Over the past decade, metabolic research has shifted significantly toward a class of compounds that interact with incretin hormone receptors — the signalling proteins that regulate how the body processes energy, manages appetite and responds to food intake.
Most people are now familiar with GLP-1. It sits at the centre of a generation of metabolic research and has become one of the most discussed mechanisms in health science. But GLP-1 is only one part of a more complex picture.
Retatrutide is a compound of growing research interest precisely because it targets three receptors simultaneously: GLP-1, GIP and GCGR. Understanding what each receptor does — and why their combined activation is scientifically significant — is the starting point for any serious study of this compound.
GLP-1: the appetite and insulin signal
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by the gut in response to food intake. It plays a central role in glucose-dependent insulin secretion, gastric emptying and appetite regulation through signalling in the hypothalamus.
GLP-1 receptor agonists have been studied extensively for their effects on glycaemic control and satiety signalling. The research interest in GLP-1 activation stems from its downstream effects on energy intake regulation — specifically, its role in reducing appetite signalling and slowing the rate at which the stomach empties.
Single GLP-1 agonists have been the subject of thousands of published studies. The compound class is well-characterised, with a substantial body of peer-reviewed literature examining mechanism, tolerability and metabolic effects.
GIP: the overlooked incretin
Glucose-dependent insulinotropic polypeptide (GIP) is the second incretin hormone and, until recently, received considerably less research attention than GLP-1. This is partly because early GIP research produced mixed results — GIP receptor agonism appeared to have limited effect in isolation in certain metabolic states.
The picture changed when researchers began examining GIP in combination with GLP-1 agonism. Studies suggested that dual GLP-1/GIP activation produced synergistic metabolic effects greater than either alone — particularly in relation to adipose tissue metabolism, bone metabolism and energy expenditure.
GIP receptors are expressed in adipose tissue, bone and the central nervous system, giving the receptor a broader metabolic footprint than originally understood. Current research interest in GIP focuses on its role in lipid metabolism, fat storage regulation and its interaction with energy balance pathways.
GCGR: the glucagon dimension
Glucagon receptor (GCGR) agonism adds a third and distinct mechanism to the Retatrutide profile. Glucagon is often understood primarily as the counter-regulatory hormone to insulin — it raises blood glucose when levels fall. But glucagon receptor signalling has a more complex role in energy metabolism.
GCGR activation has been studied for its effects on hepatic glucose output, thermogenesis and fatty acid oxidation. Research into glucagon receptor agonism in the context of metabolic compounds is focused on its potential to increase energy expenditure — essentially, to raise the rate at which the body burns energy — independently of food intake effects.
The inclusion of GCGR agonism in a triple-mechanism compound is what distinguishes the research interest in Retatrutide from dual agonist compounds. Where GLP-1 and GIP primarily influence intake and processing, GCGR may influence expenditure. The three mechanisms together represent a more complete picture of metabolic regulation than any single receptor class.
What makes a triple agonist scientifically significant
The research interest in triple agonism — sometimes called triagonism — is not simply that it activates more receptors. It is that the three receptors involved regulate distinct but interconnected aspects of metabolic function.
GLP-1 addresses appetite and insulin signalling. GIP addresses adipose tissue metabolism and synergistic incretin effects. GCGR addresses energy expenditure and hepatic function. Together, they represent three points on the energy balance equation: intake, processing and expenditure.
Retatrutide was developed by Eli Lilly and has been the subject of Phase 2 and Phase 3 clinical trials, with published results in peer-reviewed journals including the New England Journal of Medicine. The published trial data covers metabolic outcomes, tolerability profiles and dose-response relationships in human subjects.
For researchers interested in metabolic science, Retatrutide represents one of the most mechanistically complex compounds currently under active study. The published literature is accessible, substantial and growing.
A note on research context
Retatrutide is supplied by Eira London for research purposes only. It is not approved for human use, is not a licensed medicine and is not intended for self-administration. This article is an overview of the published scientific literature on the receptor mechanisms involved — it does not constitute medical advice, dosage guidance or a recommendation for any particular use.
Researchers interested in the published clinical trial data should refer to the primary literature directly, including the Phase 2 trial results published in the New England Journal of Medicine (2023).
Further reading
- Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. NEJM, 2023.
- Finan B et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine, 2013. Retatrutide Mechanism: GLP-1, GIP & GCGR Triple Agonist Explained | Eira London iology, and mechanisms of incretin hormone action. Cell Metabolism, 2013.